Mitochondrial dysfunction is a feature of the Alzheimer's disease brain [1] [2] [3] [4] [5] . Recent studies have highlighted the role of mitochondrial Ab in Alzheimer's disease pathogenesis [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Ab species have been found in the mitochondria of both Alzheimer's disease brain and transgenic mouse models of Alzheimer's disease overexpressing Ab 6, 7, 9, [13] [14] [15] [16] . Accumulation of Ab in mitochondria occurs before extracellular amyloid deposition and increases with age. Accordingly, Ab is linked to the mitochondrial malfunction observed in the Alzheimer's disease brain and mouse models of Alzheimer's disease 6, 7, 17 . For instance, increased expression of amyloid-binding alcohol dehydrogenase, an intracellular Ab-binding protein, exacerbates Ab-mediated mitochondrial and neuronal stress 8, 9 . Ab can also directly disrupt mitochondrial function, and such disruption causes oxidative stress 4, 18 . However, the essential intracellular mechanisms underlying Ab-mediated mitochondrial malfunction have yet to be elucidated.
The mitochondrial permeability transition pore (mPTP) has a central role in both necrotic and apoptotic neuronal cell death. Opening of the mPTP collapses the membrane potential and amplifies apoptotic mechanisms by releasing proteins with apoptogenic potential from the inner membrane space [19] [20] [21] . The mPTP is thought to involve the voltage-dependent anion channel in the outer membrane, the adenine nucleotide translocase in the inner membrane and CypD in the mitochondrial matrix 20, [22] [23] [24] [25] . CypD, a peptidylprolyl isomerase F, resides in the mitochondrial matrix and associates with the inner mitochondrial membrane during the opening of the mPTP. Oxidative and other cellular stresses promote CypD translocation to the inner membrane [26] [27] [28] [29] [30] [31] , and this translocation acts as a key factor to trigger the opening of the mPTP. Moreover, recent studies show that a genetic deficiency in CypD protects from Ca 2+ -and oxidative stress-induced cell death and that CypD functions as a necessary component of the mPTP 30, [32] [33] [34] . The observations that Ab progressively accumulates in brain mitochondria from individuals with Alzheimer's disease and Alzheimer's disease model mice and that oxidative stress is enhanced in an Ab-rich environment led us to explore the mechanisms underlying Ab-mediated mitochondrial dysfunction. Our present study offers new insights into the mechanism underlying CypD-dependent mPTP opening and synaptic function during the pathogenesis of Alzheimer's disease.
RESULTS

Interaction of CypD with mitochondrial Ab
In view of the increased expression of CypD associated with amyloid pathology in addition to aging ( Supplementary Fig. 1a -i online), we explored whether CypD serves as a mitochondrial target potentiating Ab-induced cellular perturbation. We first examined the interaction of CypD with Ab by surface plasmon resonance (SPR) 35, 36 . Recombinant human CypD protein ( Supplementary Fig. 2a online) bound Ab in a dose-dependent manner (Fig. 1a-f) . The CypD-Ab interaction was specific, because reversed-sequence Ab peptide showed no binding with CypD (Fig. 1c,f) , and antibodies against either Ab or CypD inhibited binding (data not shown). The equilibrium dissociation constants (K d ) for Ab40 (Ab peptide residues 1-40), Ab42 (Ab peptide residues 1-42), oligomeric Ab40 and oligomeric Ab42 were 1.7 mM, 164 nM, 227 nM and 4 nM, respectively. Therefore, Ab oligomers and Ab42 have higher affinity for binding to CypD.
To determine whether CypD and Ab actually interact in pathophysiologically relevant settings, we subjected mitochondrial proteins to immunoprecipitation with an antibody to CypD followed by immunoblotting with an antibody to Ab. CypD-Ab complexes, corresponding to Ab-immunoreactive bands, were detected in the cortical mitochondria of Alzheimer's disease brains (Fig. 1g) but not (or very little) in those of non-Alzheimer's disease control brains (Fig. 1g) . Ab-immunoreactive bands disappeared when the antibody to CypD was replaced by preimmune IgG (Fig. 1g) . Densitometry of all immunoreactive bands combined revealed that CypD-Ab complexes were increased by 10-13-fold in Alzheimer's disease cortical mitochondria compared to non-Alzheimer's disease cortical mitochondria (Fig. 1h) . In parallel, mitochondrial Ab was increased by nine-to tenfold in Alzheimer's disease brain ( Supplementary  Fig. 2b ), indicating an association between CypD-Ab complex and the presence of mitochondrial Ab. Furthermore, CypD-Ab complex was also found in the cortical mitochondria of transgenic mAPP mice overexpressing a mutant form of human amyloid precursor protein (APP) and Ab, but not in mitochondria from CypD-deficient mAPP mice (mAPP-Ppif -/-), CypD-null (Ppif -/-) or nontransgenic mice ( Fig. 1i-j) . Transgenic CypD-null mice are described in Supplementary Figure 2c -g. These results indicate that the CypD-Ab interaction occurs in Alzheimer's disease brain and transgenic mice with Alzheimer's-like pathology.
Confocal and electron microscopic studies confirmed colocalization of CypD and Ab in mitochondria (Fig. 2a-d) . In the cerebral cortices of people with Alzheimer's disease ( Fig. 2a ) and mAPP mice (Fig. 2b) , Ab and CypD colocalized extensively (Fig. 2a,b) . In the absence of antibodies to Ab and CypD (Fig. 2a,b ) or after neutralization of the antibodies with their antigens (Ab42 and CypD protein; Fig. 2a and data not shown), staining was lost. Immunogold electron microscopy with gold-conjugated antibodies to Ab42 (18-nm gold particles) and CypD (12-nm gold particles) revealed that the two different sizes of gold particles were colocalized in the Alzheimer's disease ( Fig. 2c and Supplementary Fig. 3a online) and mAPP brain mitochondria (Fig. 2d) . Two gold particles that did not overlap but were extremely close to each other may also be indicative of CypD-Ab colocalization because of the intercenter distance of the two gold particles 37 . As a positive control, we looked for Ab in the plaques of mAPP mice ( Supplementary Fig. 3g ). The gold particle labeling disappeared when antibodies to Ab42 and CypD were absent, replaced by preimmune IgG or preadsorbed with the respective antigens (Ab42 or CypD) ( Supplementary Fig. 3c -f,h,i).
CypD deficiency attenuates Ab-induced mitochondrial stress First, we assessed the capacity of cortical mitochondria for Ca 2+ uptake by measuring the disappearance of extramitochondrial free Ca 2+ from the medium after the addition of CaCl 2 pulses. The capacity for calcium uptake changed in an age-dependent manner in both nontransgenic and mAPP mice. Compared to mitochondria from mice at 3-6 months of age, nontransgenic mitochondria from 12-month-old mice showed a trend toward a reduction of the Fig. 3a) . Notably, mAPP-Ppif -/-cortical mitochondria were able to take up more Ca 2+ (591.7 ± 11.1 nmoles Ca 2+ per milligram protein and 333.3 ± 10.5 nmoles Ca 2+ per milligram protein for 6 and 12 months, respectively) than mAPP mitochondria. Similarly, the addition of cyclosporine A, an inhibitor of CypD, to mAPP cortical mitochondria showed a higher buffering capacity of Ca 2+ (Fig. 3b,c) . Nontransgenic cortical mitochondria buffered against CaCl 2 uptake (242.9 ± 13 nmoles Ca 2+ per milligram protein), and this capacity was significantly increased after preincubation with cyclosporine A (Supplementary Fig. 4a ,b online). The Ppif -/-cortical mitochondria took up CaCl 2 (900 ± 25.8 nmoles Ca 2+ per milligram protein) with a similar capacity to the cyclosporine A-treated nontransgenic mitochondria ( Supplementary Fig. 4a,b) .
To determine the function of the mPTP, we measured mitochondrial swelling in response to Ca 2+ . Cortical mitochondria from transgenic and nontransgenic mice showed swelling in response to Ca 2+ , and mAPP mitochondria showed a greater swelling at 12 months of age than did nontransgenic mitochondria, though cortical mitochondria of both nontransgenic and mAPP mice showed an age-dependent increase in swelling in response to Ca 2+ (Fig. 3d,e) . Notably, mAPP-Ppif -/-cortical mitochondria were more resistant to swelling and permeability transition induced by Ca 2+ than were mAPP mitochondria (Fig. 3d,f) . The addition of cyclosporine A to mAPP mitochondria also attenuated swelling in response to Ca 2+ (Fig. 3d,f) .
To assess the inner mitochondrial membrane potential in brain in situ, we loaded brain slices from transgenic mice with tetramethylrhodamine methyl ester (TMRM), a fluorescent probe to monitor the mitochondrial membrane potential. This indicator dye is a lipophilic cation accumulated by mitochondria in proportion to the membrane potential. Mitochondrial depolarization (disrupting or decreasing membrane potential) results in a loss of dye from the mitochondria and a decrease in mitochondrial fluorescence intensity. The intensity of TMRM staining was significantly decreased in the cerebral cortex and hippocampus of mAPP mice compared to other groups of mice (Fig. 3g) . However, mAPP-Ppif -/-mice had mitochondria that were largely resistant to the loss of inner membrane potential, showing higher TMRM staining intensity than mAPP mice (Fig. 3g) . Thus, mitochondria lacking CypD were protected from Ab-mediated swelling and opening of the membrane permeability transition pore.
To evaluate mitochondrial reactive oxygen species (ROS) generation, we gave transgenic mice MitoSox Red, a unique fluorogenic dye used for highly selective detection of superoxide production in the mitochondria of live cells. The percentage of area occupied by MitoSox Red staining was considerably increased in the cerebral cortices and hippocampi (hippocampal regions CA1 to CA3) of mAPP mice by two-to threefold compared to other groups of mice, whereas mAPP-Ppif -/-mice showed much less MitoSox staining ( Fig. 4a and Supplementary Fig. 4c,d ). These data indicate that the absence of CypD attenuates Ab-mediated mitochondrial ROS generation.
Further, mAPP mice showed an age-dependent increase in CypD translocation to the mitochondrial inner membrane (Fig. 4b) . The CypD-Ab complex was also present in the mitochondrial inner membrane of mAPP mice (Fig. 4c) .
Next, we assessed mitochondrial function by measuring oxygen consumption, the activity of cytochrome c oxidase (COX IV) and ATP abundance in transgenic mouse brains. Compared to Ppif -/-and nontransgenic mice, mAPP mice showed a reduction in ADP-induced respiration control rate (RCR) at 6 and 12 months of age, whereas mAPP-Ppif -/-mice had a diminished reduction in RCR (Fig. 4d) . Because mitochondria from mAPP mice had an impaired calcium capacity, we determined the effect of calcium on RCR. Calciuminduced RCR was decreased in 12-month-old mAPP cortical mitochondria but not in mAPP-Ppif -/-mitochondria as compared with nontransgenic mitochondria (Fig. 4e) . Additionally, mAPP mice had a reduced COX IV activity (Fig. 4f) and ATP abundance (Fig. 4g) , whereas mAPP-Ppif -/-mice had markedly increased mitochondrial enzyme activity and ATP abundance (Fig. 4f,g ). The COX IV activity and ATP abundance in nontransgenic mice were comparable to those in the Ppif -/-mice (Fig. 4f,g ). Similarly, CypD-deficient mitochondria were also resistant to exogenous Ab-mediated impairment in calcium capacity, swelling, CypD translocation and cytochrome c release ( Supplementary Fig. 5 online) . These data indicate that CypD deficiency attenuates or protects against Ab-mediated mitochondrial dysfunction.
CypD-Ab interaction induces neuronal death
To directly determine the effects of CypD deficiency on Ab-and oxidative stress-induced neuronal death, we examined cultured cortical neurons from nontransgenic and Ppif -/-mice (Supplementary Fig. 6a online) . The CypD-Ab complex was detected in nontransgenic cortical neurons but not in Ppif -/-neurons exposed to Ab ( Supplementary Fig. 6b ). Incubation of Ab42 with nontransgenic cortical neurons reduced mitochondrial membrane potential, as shown by TMRM staining, in a time-and dose-dependent manner, whereas Ppif -/-neurons had attenuated Ab-induced reduction of the mitochondrial membrane potential (Fig. 5a,b) . Consequently, Ab-treated nontransgenic cortical neurons showed increased cytochrome c release as compared to Ab-treated Ppif -/-and vehicletreated neurons (Fig. 5c) . number of TUNEL-positive cells in Ppif -/-neurons exposed to Ab (Fig. 5d ). The addition of cyclosporine A had a similar effect on Ab-induced apoptosis (Fig. 5d) . Because CypD deficiency attenuated ROS generation (Fig. 4a ) in mAPP mice, we evaluated the direct effect of CypD deficiency on oxidative stress-induced mitochondrial and neuronal toxicity. Flow cytometry analysis of fluorescently labeled cells showed a marked dose-dependent reduction in the number of TMRM-positive cells in both nontransgenic and Ppif -/-neurons exposed to increasing concentrations of H 2 O 2 . However, Ppif -/-neurons were more resistant to H 2 O 2 -induced loss of membrane potential than were nontransgenic neurons, as shown by a higher percentage of TMRM-positive cells amongst H 2 O 2 -treated Ppif À/À neurons (31.8%) compared to H 2 O 2 -treated nontransgenic neurons (5.5%; Fig. 5e,f) . A protective effect of CypD deficiency on H 2 O 2 -mediated reduction in membrane potential was further evaluated by measuring the percentage of TMRM-labeled living cells with fluorescent microscopy (Supplementary Fig. 6c ). FACS analysis revealed significant increases in propidium iodide- (Fig. 5g,h ) and annexin V- (Fig. 5i,j) positive cells after H 2 O 2 treatment in nontransgenic neurons, whereas Ppif -/-neurons were protected from H 2 O 2 -induced cell death (Fig. 5g-j) .
CypD deficiency improves behavioral and synaptic function
The radial arm water maze test was used to assess the spatial learning and memory of transgenic mice. At 6 and 12 months of age, Ppif -/-and nontransgenic mice showed a strong learning and memory capacity (Fig. 6a,b) , whereas mAPP mice showed impaired spatial learning and memory for the platform location during trial 4 and retention test (average of about five or six errors by trial 4 and the retention test). The mAPP-Ppif -/-mice had substantially improved spatial learning and memory (approximately two or three errors by trial 4 and the retention test; Fig. 6a,b) , indicating that the absence of CypD improves learning and memory in mice with Alzheimer's-like disease.
Given that mAPP-Ppif -/-mice showed an improvement in learning and memory, we examined whether these mice also had an improvement in long-term potentiation (LTP), a form of synaptic plasticity that is widely studied as a cellular model for learning and memory. Slices from 12-13-month-old mAPP mice showed a reduction in LTP compared to slices from nontransgenic littermates (140.99 ± 11.81% at 120 min after the tetanus versus 218.52 ± 24.38%; n ¼ 10-12, P o 0.05; Fig. 6c ). Slices from mAPP-Ppif -/-littermates, in turn, showed normal LTP (199.32 ± 20.01%; n ¼ 13, P o 0.05 compared to mAPP mice and P 4 0.05 compared to nontransgenic mice; Fig. 6c ) and improved basal synaptic transmission compared to mAPP slices ( Supplementary Fig. 6d ). The Ppif -/-slices also showed a normal LTP (184.70 ± 16.47%; n ¼ 10, P 4 0.05 compared to nontransgenic slices). To test a direct effect of CypD deficiency on Ab-mediated reduction of LTP, we recorded LTP in hippocampal slices from Ppif -/-and nontransgenic mice treated with Ab. We found similar amounts of potentiation in CypD-deficient slices compared to nontransgenic slices in the presence of vehicle (230.06 ± 24.71% versus 209.39 ± 15.77%, n ¼ 6 or 7, P 4 0.05; Fig. 6d ). However, CypD deficiency protected hippocampal slices against a reduction of LTP by 200 nM oligomeric Ab42 (206.42 ± 17.35% in Ab-treated Ppif -/-slices versus 163.91 ± 17.36% in Ab-treated nontransgenic slices; n ¼ 7-9, P o 0.05; Fig. 6d ). Basal synaptic transmission was not affected in the Ppif -/-mice. The addition of cyclosporine A (1 mM) rescued Ab-induced reduction of LTP in nontransgenic hippocampal slices (219.61 ± 30.27% after treatment with cyclosporine A and Ab versus 145.96 ± 13.09% after Ab treatment; n ¼ 7 or 8, P o 0.05; Fig. 6e ). Cyclosporine A alone did not alter LTP (232. 43 ± 23.19% in cyclosporine A-treated slices versus 227.57 ± 24.16% in vehicletreated nontransgenic slices; n ¼ 6 or 7, P 4 0.05; Fig. 6e) . These results confirm previous data showing that Ab impairs LTP 38 . Most notably, they indicate that CypD deficiency may protect against the deleterious effects of Ab soluble oligomers on synaptic function. We next determined whether Ab-mediated reduction of LTP can be prevented by ROS scavenging. The addition of 100 U ml -1 superoxide dismutase (SOD, a scavenger of superoxide, converting it into oxygen and hydrogen peroxide) plus 260 U ml -1 catalase (to prevent inhibition of LTP by H 2 O 2 through its conversion into oxygen and water 39, 40 ) blocked Ab-induced inhibition of LTP in nontransgenic hippocampal slices (220.89 ± 30.97% in SOD-, catalase-and Ab-treated slices versus 145.37 ± 12.24% in Ab alone-treated nontransgenic slices; n ¼ 7 or 8, P o 0.05; Fig. 6f ). SOD plus catalase did not alter LTP (205.05 ± 11.79% in SOD-and catalase-treated slices versus 219.30 ± 24.42% in vehicle-treated nontransgenic slices; n ¼ 6-8, P 4 0.05; Fig. 6f) . These experiments suggest a role for ROS in Ab-mediated impairment of LTP.
DISCUSSION
Our data show that the expression of CypD is associated with amyloid pathology and aging in the brain. The increased expression of CypD could be an explanation for the observed aging-and Ab-related impairment of mitochondrial function, as CypD is a key component of the mPTP, and its abundance is associated with the vulnerability of the mPTP to Ca 2+ (refs. 41,42) . Our studies indicate that the genetic removal of this Ab binding partner, within Ab-containing mitochondria, improves mitochondrial, neuronal and synaptic function. Therefore, it will be useful to understand the structural basis of the CypD-Ab interaction, and further investigation by crystallization and mutational analysis is required to identify the amino acid sequences of CypD responsible for its binding to Ab.
Although Ab can directly disrupt mitochondrial function and cause oxidative stress 18, 43, 44 , the interaction of mitochondrial Ab with CypD significantly enhances the accumulation and production of mitochondrial ROS, which is a strong inducer for the recruitment of CypD to the mitochondrial inner membrane. In addition, other stimuli such as ROS, directly produced by Ab itself or by the interaction of Ab with mitochondrial amyloid-binding alcohol dehydrogenase 8, 9 , could result in CypD recruitment, leading to mPTP opening, loss of membrane potential and, eventually, cell death. The excessive ROS will exaggerate oxidative damage and mitochondrial malfunction, including the collapse of the membrane potential 9, 45, 46 . This is evident in CypD-deficient mAPP mice, which had a reduction in the accumulation of mitochondrial ROS in conjunction with a higher mitochondrial polarization.
Finally, deficiency of CypD significantly improved cognitive and synaptic function in a mouse model of Alzheimer's disease. The addition of ROS-scavenging enzymes alleviated Ab-mediated reduction of LTP. These results, combined with the evidence that lack of CypD attenuated ROS generation and protected neurons from Ab-and oxidative stress-induced injury, indicate that oxidative damage induced by the CypD-Ab interaction may be a mechanism underlying the impairments in synaptic plasticity and memory in Alzheimer's disease [47] [48] [49] . Mitochondria can also become severely dysfunctional through the permeability transition induced by the synergistic effects of oxidative stress and dysregulation of cytosolic free Ca 2+ . Therefore, synaptic and memory dysfunction mediated by Ab binding to CypD may involve other mechanisms such as Ca 2+ -regulated signaling pathways, oxidative stress-mediated kinase systems and activation of transcription factors 38, [50] [51] [52] [53] . Further investigations are required to elucidate these alternative mechanisms.
Taken together, our studies have clearly shown that CypD and Ab directly interact with each other in the mitochondria of Alzheimer's disease brain and in a transgenic mouse model of Alzheimer's disease. This CypD-Ab interaction promotes ROS generation and CypD recruitment to the mitochondrial inner membrane, leading to the formation of the mPTP. CypD-mediated mPTP formation has a crucial role in regulating mitochondrial-induced cell death in an Ab-rich environment, although the openings in the outer mitochondrial membrane associated with activation of members of the Bcl-2 family, either proapoptotic (Bax, BAD and Bak among others) or antiapoptotic (Bcl-2, Bcl-xL and Bcl-w, among others) proteins (such as the accumulation of Bax at the outer mitochondrial membrane induced by intracellular Ab), may also contribute to neurotoxicity 54 . Our studies provide new insights into the mechanism underlying Ab-mediated mitochondrial stress through an interaction with CypD. The absence of CypD protects neurons from Ab-and oxidative stress-induced cell death, impaired learning and memory and synaptic dysfunction. Therefore, CypD is a key mitochondrial target for Ab-induced mitochondrial and synaptic dysfunction. Blockade of CypD may be a potential therapeutic approach for halting Alzheimer's disease.
METHODS
Mice. Mouse studies were approved by the Animal Care and Use Committee of Columbia University in accordance with the US National Institutes of Health guidelines for animal care. We crossed transgenic mice overexpressing a mutant human form of amyloid precursor protein (mAPP, J-20 line) 9, 50 with Ppif -/-mice 30 to generate CypD-deficient mAPP mice (mAPP-Ppif -/-).
Human tissues. We obtained human brain tissues of temporal cortex (temporal pole, including Brodmann area 38, which is the apparent rostral origin of the superior, middle and inferior temporal gyri) and hippocampus from individuals with Alzheimer's disease and age-matched, non-Alzheimer's disease controls from New York Brain Bank at Columbia University. Detailed information for each of the cases studied is shown in Supplementary Table 1 online. We obtained informed consent from all subjects. The study was approved by the Institutional Review Board of Columbia University.
Isolation of mitochondria. We isolated mitochondria from the cortices of Alzheimer's disease brains or cortices of mouse brains as previously described 6, 9 . We used the highly purified mitochondria for immunoblotting and immunoprecipitation. For the mitochondrial function assay, mitochondria were isolated by centrifuging brain homogenates at 1,500g for 5 min at 4 1C. We adjusted the supernatant to 10% Percoll and recentrifuged at 12,000g for 10 min. We resuspended the mitochondrial pellet in the isolation buffer (225 mM D-mannitol, 75 mM sucrose, 2 mM K 2 HPO 4 , 5 mM HEPES, pH 7.2) containing 0.01% digitonin and recentrifuged at 6,000g for 10 min. We isolated cell mitochondria with a mitochondrial fractionation kit (Active Motif). We determined protein concentration by the Bio-Rad DC protein assay (BioRad).
Immunoblotting analysis. We subjected mitochondrial proteins to immunoblotting with antibody to CypD (1 mg ml -1 , generated in our laboratory) followed by goat antibody to rabbit IgG conjugated with peroxidase to determine the expression level of CypD. We used chemiluminescent substrate (Roche) to detect the CypD immunoreactive band. We reprobed the membrane with antibody to COX IV (to human COX IV, Invitrogen; or to mouse COX IV, Abcam).
Immunoprecipitation and immunoblotting for detection of CypD-Ab complex. We resuspended mitochondria from cerebral cortices of transgenic mice or human subjects in buffer (500 mg ml -1 , 50 mM Tris, 150 mM NaCl, 1 mM EDTA, protease inhibitors (Calbiochem, set V, EDTA free), 0.1% NP-40, pH 7.5) and subjected them to five freeze-thaw cycles, followed by centrifugation at 14,000g for 5 min at 4 1C. We immunoprecipitated the resulting supernatant with rabbit antibody to CypD (1:500 dilution) at 4 1C overnight, followed by a second incubation with protein A/G (Pierce) for 2 h at 20 1C. We subjected the resultant immunoprecipitant to immunoblotting with antibody to Ab (6E10,1:3,000, Signat).
Surface plasmon resonance study of CypD-Ab interaction. See Supplementary Methods online.
Immunostaining for confocal and electron microscopy study. See Supplementary Methods online.
Mitochondrial function assays. We monitored mitochondrial oxygen consumption with a Clark oxygen electrode (Oxytherm, Hansatech) as previously described 6 .
We performed the mitochondrial swelling assay according to a previously published method 34 with modifications (Supplementary Methods).
We measured mitochondrial calcium retention capacity with the fluorescent indicator Calcium Green 5N (Invitrogen). We suspended mitochondria (100 mg) at 20 1C in 1 ml respiration buffer (150mM KCl, 5mM HEPES, 2mM K 2 HPO 4 , pH 7.2) containing 1 mM Calcium Green 5N with pulsate injection of calcium into the cuvette. We monitored fluorescence with an excitation of 506 nm and an emission of 531 nm with a FluoroMax-2 spectrophotometer (Jobin Yvon-Spex Instruments).
We measured cytochrome c release, activity of COX IV and ATP abundance in brain as described in the Supplementary Methods.
In situ detection of mitochondrial reactive oxygen species and membrane potential. We performed in situ measurements of ROS in brain slices as previously described 55 with modifications. We injected MitoSox Red (1mg kg -1 , Invitrogen) intravenously via the tail vein. After 30 min, we anesthetized the mice with ketamine (100 mg kg -1 ) and xylazine (10 mg kg -1 ) and killed them by transcardial perfusion with cold saline (5 min) and then cold, freshly prepared 3.7% paraformaldehyde (3 min). We quickly removed the brain and froze it in 2-methyl butane with dry ice. We immediately cut coronal frozen brain sections (6 mm) and mounted them with DAPI-containing mounting medium (Vector Laboratories). We examined sections under a fluorescence microscope immediately after the mounting. We analyzed the area occupied by MitoSox Red staining with the Universal image program. Brain sections from mice were blindly coded and processed in parallel. Codes were broken after the analysis was complete.
For evaluation of membrane potential, we perfused anesthetized mice with cold saline for 3 min. We incubated frozen brain sections with TMRM (50 nM, Invitrogen) in PBS for 15 min. We quantified the intensity of TMRM staining with the Universal image program.
CypD translocation. We examined CypD translocation to the inner membrane as previously described 28, 56 (Supplementary Methods).
Determination of cytochrome c release, membrane potential and apoptosis in cultured neurons. We incubated primary cultured neurons with Ab (2-5 mM) for 12-24 h or with H 2 O 2 (0.5, 2 and 5 mM) for 1 h and then treated them with TMRM (100 nM) for 30 min. We observed the cells under a microscope or trypsinized them for detection of TMRM by flow cytometry (Becton Dickinson FACS Calibur). We analyzed flow cytometric data by Flowjo 7 (Tree Star).
We assessed cytochrome c release by immunoblotting with antibody to cytochrome c (Invitrogen). We determined apoptosis by detecting TUNELpositive cells using an in situ cell death detection kit (Roche). We analyzed propidium iodide-or annexin V-labeled cells by flow cytometry.
Behavioral and electrophysiological studies. We performed behavioral studies to assess spatial learning and memory in the radial arm water maze as previously described 9, 50 . We performed the retention tests 30 min after the fourth test. The four groups of mice in the behavioral studies were littermates and gender-matched to enhance the reproducibility and reliability of our results in the radial arm water maze. Investigators were unaware of mouse genotypes until the behavioral tests were finished.
We performed electrophysiological recordings on transverse hippocampal slices (400 mm in thickness) as previously described 38 (Supplementary Methods).
Statistical analyses. We performed statistical analyses with Student's t-test and one-way analysis of variance using the Statview statistics software. P o 0.05 was considered significant. All data are expressed as means ± s.e.m. 
